coding sequences for p1 (ATCC)
Structured Review

Coding Sequences For P1, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1123 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/coding sequences for p1/product/ATCC
Average 97 stars, based on 1123 article reviews
Images
1) Product Images from "Three-Component Subunit Vaccine Induces Protective Immunity Against Mycoplasma pneumoniae in Mice"
Article Title: Three-Component Subunit Vaccine Induces Protective Immunity Against Mycoplasma pneumoniae in Mice
Journal: Vaccines
doi: 10.3390/vaccines14040330
Figure Legend Snippet: Recombinant protein design, construction, and purity validation. ( A ) Schematic diagram of recombinant protein constructs. Mutation sites are indicated by short black lines. ( B – H ) SDS-PAGE, Western blot, and Superdex™ 200 Increase 10/300 GL purification results for recombinant proteins. ( B ) P1 (~165 kDa); ( C ) P40/90 complex (~117 kDa); ( D ) CARDS-WT (~69 kDa); ( E ) CARDS-E132A (~69 kDa); ( F ) CARDS-E132Q (~69 kDa); ( G ) CARDS-H36A (~69 kDa); ( H ) CARDS-R10A (~69 kDa). Left lane: protein marker; right lane: purified recombinant protein.
Techniques Used: Recombinant, Biomarker Discovery, Construct, Mutagenesis, SDS Page, Western Blot, Purification, Marker
Figure Legend Snippet: Toxicity screening of CARDS mutants and purity analysis of recombinant proteins. ( A ) Dose–response curves of TNF-α secretion from RAW264.7 cells treated with CARDS-WT and various mutants, used for screening attenuated mutants. ( B – H ) HPLC chromatograms of recombinant proteins on TSKgel G2000SWXL column. Purity values are indicated above the main peaks: ( B ) CARDS-E132A (78.88%), ( C ) CARDS-E132Q (73.47%), ( D ) CARDS-H36A (86.99%), ( E ) CARDS-R10A (82.72%), ( F ) P1 (87.65%), ( G ) P40/90 (96.76%), ( H ) CARDS-WT (91.77%).
Techniques Used: Recombinant
Figure Legend Snippet: Formulation, immunization schedule, and antigen-specific IgG antibody responses of the three-component M. pneumoniae vaccine. ( A ) Formulation scheme showing the 6 experimental groups, their respective vaccine and adjuvant combinations. ( B ) Immunization schedule showing time points for immunizations (days 0, 14, 28) and serum collection (days 13, 27, 41). ( C – F ) Serum titers (log10) of specific IgG antibodies against P1, P40/90, CARDS-WT, and CARDS-Mut following single antigen immunizations (days 0, 14, 28) and serum collection (days 13, 27, 41). The saline group served as the negative control. ( G – J ) Serum antibody titers (days 41) against P1, P40/90, CARDS-WT, and CARDS-Mut in mice immunized according to the groups shown in ( A ). ( K ) Comparison of antibody titers (days 41) between the MPtriVa-D group (containing CARDS-WT with dual adjuvant) and the MPtriVb-D group (containing CARDS-Mut with dual adjuvant). ( L ) Comparison of antibody titers (days 41) between the MPtriVb-S (single adjuvant) and MPtriVb-D (dual adjuvant) groups. Data are presented as mean ± SD. p > 0.05 (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
Techniques Used: Formulation, Adjuvant, Saline, Negative Control, Comparison
